At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Sep 11, 2026 at 16:13 ET
GeneDx Holdings CEO Katherine Stueland and CFO Kevin Feeley sold a combined $419K in open-market shares on September 9, 2026, at $84.22 per share. The sales followed non-cash derivative exercises by both executives on the same day, suggesting a tax- or liquidity-driven pattern rather than a coordinated bearish signal. At $2.5B market cap, the sales represent ~0.017% of market cap, well below the 0.1% materiality threshold.
- CEO Stueland sold 3,692 shares at $84.22 for $311K
- CFO Feeley sold 1,285 shares at $84.22 for $108K
- Both executives exercised derivative options at $0 on the same day before selling
- Total open-market sales of $419K represent ~0.017% of $2.5B market cap
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access